Overview

Pegaferon and Ribavirin for Hepatitis C

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of a locally produced 40KD pegylated interferon alpha-2a (Pegaferon) in patients with hepatitis C. 100 patients will be treated using standard guidelines for hepatitis C. Response to treatment and side effects will be recorded.

Phase:

Phase 3

Details

Lead Sponsor:

Tehran University of Medical Sciences

Collaborator:

Pars No Tarkib Co

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin